0.7626
5.07%
0.0368
Precigen Inc 주식(PGEN)의 최신 뉴스
Fmr LLC Has $327,000 Stake in Precigen, Inc. (NASDAQ:PGEN) - Defense World
Analysts Update Their Estimates For Precigen Inc - Stocks Register
Metastatic Triple Negative Breast Cancer Market Expected to Experience Major Growth by 2034, According to DelveInsight | AstraZeneca, BioEclipse Therapeutics, Precigen, Inc, Clovis Oncology, Inc - Barchart
Further weakness as Precigen (NASDAQ:PGEN) drops 16% this week, taking five-year losses to 89% - Simply Wall St
Precigen's SWOT analysis: biotech firm's stock rides on PRGN-2012 hopes - Investing.com
PGEN Stock Touches 52-Week Low at $0.71 Amid Market Challenges - Investing.com Canada
Precigen to Participate in the 2024 Cantor Global Healthcare Conference - The Eastern Progress Online
Precigen to Participate in the Stifel 2024 Healthcare Conference - The Eastern Progress Online
PGEN Stock Plummets to 52-Week Low at $0.77 Amid Market Challenges - Investing.com Nigeria
PGEN Stock Plummets to 52-Week Low at $0.77 Amid Market Challenges By Investing.com - Investing.com South Africa
Precigen (STU:I5X) Shares Outstanding (EOP) : 292.87 Mil (As of Sep. 2024) - GuruFocus.com
Precigen, Inc. (NASDAQ:PGEN) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Bioinformatics Market to Grow by USD 13.2 Billion (2024-2028), Lower Genetic Sequencing Costs Drive Revenue, Report Highlights AI's Role in TransformationTechnavio - The Malaysian Reserve
Precigen's SWOT analysis: biotech stock focuses on RRP treatment - Investing.com
Precigen's SWOT analysis: biotech stock focuses on RRP treatment By Investing.com - Investing.com Australia
Precigen Reports Q3 2024 Financial Results - MSN
Insiders Sold Precigen Prematurely At US$1.41 With Stock Trading Higher - Simply Wall St
Precigen (NASDAQ:PGEN shareholders incur further losses as stock declines 13% this week, taking five-year losses to 86% - Yahoo Finance
Precigen, Inc. (PGEN) Reports Q3 Loss, Lags Revenue Estimates - MSN
Precigen (NASDAQ:PGEN) Given Buy Rating at HC Wainwright - Defense World
HC Wainwright Issues Negative Outlook for Precigen Earnings - MarketBeat
PGEN stock touches 52-week low at $0.78 amid market challenges - Investing.com Canada
HC Wainwright Reiterates Buy Rating for Precigen (NASDAQ:PGEN) - MarketBeat
Precigen Inc. (PGEN) Quarterly 10-Q Report - Quartz
Precigen Inc (PGEN) Q3 2024 Earnings: EPS Misses at $(0.09), Rev - GuruFocus.com
Precigen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Precigen earnings missed, revenue fell short of estimates By Investing.com - Investing.com UK
Precigen Reports Third Quarter 2024 Financial Results and Business Updates - Nasdaq
Precigen (NASDAQ:PGEN) Shares Cross Below Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Precigen CEO to Present at Stifel 2024 Healthcare Conference: Gene Therapy Innovation Spotlight | PGEN Stock News - StockTitan
Precigen, Inc. (NASDAQ:PGEN) Receives $7.00 Consensus Price Target from Brokerages - Defense World
Precigen, Inc. (NASDAQ:PGEN) Receives $7.00 Consensus Target Price from Analysts - MarketBeat
PGEN (Precigen) EBITDA per Share : $-0.52 (TTM As of Jun. 2024) - GuruFocus.com
Precigen Announces Pricing of $30.0 Million Public Offering of C - GuruFocus.com
Iridian Asset Management LLC CT Grows Stock Position in Precigen, Inc. (NASDAQ:PGEN) - MarketBeat
PGEN stock touches 52-week low at $0.82 amid market challenges - Investing.com Australia
Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th - GuruFocus.com
High Growth Tech Stocks To Watch In October 2024 - Simply Wall St
Should you Hold Precigen (PGEN)? - Insider Monkey
Precigen, Inc. (NASDAQ:PGEN) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
A company insider recently bought 58,823 shares of Precigen Inc [PGEN]. Should You Buy? - Knox Daily
Precigen reclaims rights after terminating license agreement By Investing.com - Investing.com Australia
Precigen Inc (PGEN) stock analysis: A simple moving average approach - US Post News
Precigen reclaims rights after terminating license agreement - Investing.com India
Alaunos Therapeutics Ends Licensing Deal, Reassesses Strategy - Yahoo Finance
Precigen Terminates License Agreement With Alaunos Therapeutics - MarketWatch
자본화:
|
볼륨(24시간):